These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 27327527)

  • 1. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
    Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
    Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET of brain amyloid and tau in mild cognitive impairment.
    Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
    N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.
    Barrio JR; Kepe V; Satyamurthy N; Huang SC; Small G
    J Nutr Health Aging; 2008 Jan; 12(1):61S-5S. PubMed ID: 18165848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal tau PET in ageing and Alzheimer's disease.
    Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
    Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET and amyloid-PET imaging: the diverging paths.
    Perani D
    Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau positron emission tomography in preclinical Alzheimer's disease.
    Insel PS; Young CB; Aisen PS; Johnson KA; Sperling RA; Mormino EC; Donohue MC
    Brain; 2023 Feb; 146(2):700-711. PubMed ID: 35962782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.
    Scott MR; Hampton OL; Buckley RF; Chhatwal JP; Hanseeuw BJ; Jacobs HI; Properzi MJ; Sanchez JS; Johnson KA; Sperling RA; Schultz AP
    Neuroimage; 2020 Oct; 220():116991. PubMed ID: 32512123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
    Pascoal TA; Mathotaarachchi S; Mohades S; Benedet AL; Chung CO; Shin M; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P
    Mol Psychiatry; 2017 Feb; 22(2):306-311. PubMed ID: 27021814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
    Dronse J; Fliessbach K; Bischof GN; von Reutern B; Faber J; Hammes J; Kuhnert G; Neumaier B; Onur OA; Kukolja J; van Eimeren T; Jessen F; Fink GR; Klockgether T; Drzezga A
    J Alzheimers Dis; 2017; 55(2):465-471. PubMed ID: 27802224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.